<!DOCTYPE html>
<html lang="en-US">
    <head>
        <meta charset="utf-8"/>
        <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
        <link rel="stylesheet" href="mystyles.css">
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Yellowtail">
        <title>Research</title>
        <link rel="icon" type="image/x-icon" href="../images/favicon.ico">
    </head>
    <body>
        <header>
            <div class="nav-container">
                <a class="left-justify" href="index.html">Shane Carr</a>
                <nav class="navbar" id="navbar">
                    <ul>
                        <li><a class="unbold-nav vanish" href="index.html">Home</a></li>
                        <li><a class="unbold-nav vanish" href="curriculum.html">Curriculum Vitae</a></li>
                        <li><a class="bold-nav vanish" href="research.html">Research</a></li>
                        <li><a class="unbold-nav vanish" href="artwork.html">Art</a></li>
                        <li><a class="unbold-nav vanish" href="#contact">Contact</a></li>
                        <li><a class="vanish"><button class="icon-sun-icon" id="dark-mode-button"></button></a></li>
                    </ul>
                </nav>
                <div class="menu-button">
                    <div class="button-visual"></div>
                </div>
            </div>
        </header>
        <main>
            <section id="research-anes" class="research-section">
                <h2 class="research-heading">Anesthesiology Postoperative Outcomes</h2>
                <div class="spacer">
                    <p class="research-text">Postoperative pulmonary complications (PPCs) are fairly common and result in an increased mortality, hospital stay, and cost of care. These PPCs are linked to residual neuromuscular blockade due to incomplete reversal prior to extubation. While reversal agents, like sugammadex, have been shown to be associated with a decrease in PPCs, there is still a risk of residual neuromuscular blockade when neuromuscular monitoring with the train-of-four (TOF) is not used. At our institution, only 42% of cases used TOF.</p>
                    <div class="spacer"></div>
                    <img class="research-image-anes" src="../images/ANES1.PNG">
                    <div class="spacer"></div>
                    <p class="research-text">My research with Dr. Miklos Kertai saught to determine whether a series of educational initiatives could significantly raise the rate of TOF monitoring at our institution. We also compared cases with TOF monitoring to those without to see if TOF was associated with a decreased risk of PPCs and mortality. This project is ongoing and will be presented at the American Society of Anesthesiologists 2022.</p>
                </div>
            </section>
            <section id="research-phtn" class="research-section">
                <h2 class="research-heading">Molecular Mechanisms of Pulmonary Arterial Hypertension</h2>
                <div class="spacer"></div>
                <div class="research-grid">
                    <div class="research-phtn-i1">
                        <p class="research-text-pic">Normal Pulmonary Arteriole Cross-section</p>
                        <img class="research-image-phtn" src="../images/PHTN1-1.PNG">
                        <p class="research-text-pic">Pulmonary Arteriole With Smooth Muscle Cell Proliferation</p>
                        <img class="research-image-phtn" src="../images/PHTN1-2.PNG">
                    </div>
                    <div class="research-phtn-p1">
                        <p class="research-text">Pulmonary arterial hypertension (PAH) is a progressive and fatal disease characterized by aberrant proliferation of the vascular wall smooth muscle cells. This thickening results in decreased luminal area and subsequent increase in pulmonary arterial pressure.</p>
                        <p></p>
                        <p class="research-text">Why does this happen?</p>
                        <p></p>
                        <p class="research-text">The answer is still being studied. My research in the lab of Dr. Jason Yuan looked at several mechanisms involved. First, it appears that the pulmonary arterial smooth muscle cells from patients with PAH have an increased cytosolic calcium level. We studied proteins involved in calcium signaling to find potential targets in reducing cellular calcium concentrations and therefore preventing excessive smooth muscle cell growth.</p>
                    </div>
                    <div class="research-phtn-p2">
                        <p class="research-text">We also studied the role of the tumor suppressor protein, p53, in the development of PAH. In mice with induced PAH, p53 was decreased in the pulmonary arterial smooth muscle cells, indicating a lack of growth suppression.</p>
                        <p></p>
                        <p class="research-text">To read the publications, follow the links below:</p>
                        <ul>
                        <li class="research-text"><a class="research-link" href="https://pubmed.ncbi.nlm.nih.gov/29358461/" target="_blank">Calcium sensor Stromal-interaction molecule 2 (STIM-2) and PAH</a></li>
                        <li class="research-text"><a class="research-link" href="https://pubmed.ncbi.nlm.nih.gov/30358436/" target="_blank">Tumor suppressor p53 and PAH</a></li>
                        <li class="research-text"><a class="research-link" href="https://pubmed.ncbi.nlm.nih.gov/33294172/" target="_blank">Platelet-derived growth factor and PAH</a></li>
                        <li class="research-text"><a class="research-link" href="https://pubmed.ncbi.nlm.nih.gov/33694155/" target="_blank">Potential treatment of PAH with Halofuginone</a></li>
                        </ul>
                    </div>
                    <div class="research-phtn-i2"><img class="research-image-phtn2" src="../images/PHTN2.PNG"></div>
                </div>
                <div class="spacer"></div>
            </section>
        </main>
        <footer id="contact"> 
            <div class="footer-container">
                <div class="footer-logo">
                    <p class="footer-logo-text">SC</p>
                </div>
                <div class="footer-contact">
                    <p class="footer-text-bold">Contact Shane Carr</p>
                    <p class="footer-text">Email: shane.g.carr@vanderbilt.edu</p>
                    <p class="footer-text">Phone: (480)-209-2914</p>
                </div>
            </div>
        </footer>
        <script src="../scripts/darkmode.js"></script>
        <script src="../scripts/menu-button.js"></script>
    </body>
</html>